Coronavirus Update: Gilead Ready To Unveil Remdesivir Price
Plus Developments From Vir and Eli Lilly
Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.
You may also be interested in...
Working with the US agency for two years, was primed to respond, and is competing with and Regeneron to bring a COVID-19 therapy to patients before the end of 2020.
Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.